Δ9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 1, 2005, Pages 329-337

  Varvel, S A ^a   Bridgen, D T ^a   Tao, Q ^a   Thomas, B F ^b   Martin, B R ^a   Lichtman, A H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DRONABINOL; PLACEBO; RIMONABANT; ANALGESIC AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; CATALEPSY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EXPERIMENT; EXPOSURE; EXTRACTION; HYPOTHERMIA; HYPOTHESIS; INHALATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOKE; ANIMAL; ANIMAL BEHAVIOR; BODY TEMPERATURE; BRAIN; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PAIN ASSESSMENT;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; BRAIN; CANNABIS; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; INHALATION EXPOSURE; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED ICR; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; SMOKE; TETRAHYDROCANNABINOL;

EID: 23044447712     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.080739     Document Type: Article

References (28)

1. Baker D, Pryce G, Giovannoni G, and Thompson AJ (2003) The therapeutic potential of cannabis. Lancet Neurol 2:291-298.
2. Bliss CI (1967) Statistics in Biology: Statistical Methods for Research in the Natural Sciences, McGraw-Hill, New York.
3. Bornheim LM, Kim K, Beatrice J, Perotti Y, and Benet L (1995) Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23:825-831.
4. Colquhoun D (1971) Lectures on Biostatistics: An Introduction to Statistics with Applications in Biology and Medicine, Clarendon Press, Oxford, UK.
5. Croxford JL (2003) Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17:179-202.
6. 9-tetrahydrocannabinol effects. Clin Pharmacol Ther 19:300-309.
7. D'Amour FE and Smith DL (1941) A method for determining loss of pain sensation. J Pharm Exp Ther 72:74-79.
8. Drysdale AJ and Platt B (2003) Cannabinoids: mechanisms and therapeutic applications in the CNS. Curr Med Chem 10:2719-2732.
9. ElSohly M (2002) Chemical constituents of cannabis, in Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential (Grotenhermen FRE ed) pp 27-36, Haworth Press, Binghamton, NY.
10. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B and Banahan BF, 3rd (2000) Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 45:24-30.
11. Fadda P, Robinson L, Fratta W, Pertwee RG, and Riedel G (2004) Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47:1170-1179.
12. Finn DP, Beckett SR, Roe CH, Madjd A, Fone KC, Kendall DA, Marsden CA, and Chapman V (2004) Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci 19:678-686.
13. GW Pharmaceuticals (2003) Cannabis-based medicines-GW pharmaceuticals: high CBD, high THC, medicinal cannabis-GW pharmaceuticals, THC:CBD. Drugs RD 4:306-309.
14. Jarbe TU, Henriksson BG, and Ohlin GC (1977) Delta9-THC as a discriminative cue in pigeons: effects of delta8-THC, CBD and CBN. Arch Int Pharmacodyn Ther 228:68-72.
15. 9-tetrahydrocannabinol. Psychopharmacology 33:53-70.
16. Lichtman AH, Poklis JL, Poklis A, Wilson DM, and Martin BR (2001) The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend 63:107-116.
17. Meng Y, Lichtman AH, Bridgen DT, and Martin BR (1997) Inhalation studies with drugs of abuse. NIDA Res Monogr 173:201-224.
18. Pertwee RG (1972) The ring test: A quantitative method for assessing the "cataleptic" effect of cannabis in mice. Br J Pharmacol 46:753-763.
19. Petitet F, Jeantaud B, Reibaud M, Imperato A, and Dubroeucq M (1998) Complex pharmacology for natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:PL1-PL6.
20. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
21. Rosenkrantz H and Hayden DW (1979) Acute and subacute inhalation toxicity of turkish marihuana, cannabichromene and cannabidiol in rats. Toxicol Appl Pharmacol 48:375-386.
22. Takahashi RN and Karniol IG (1975) Pharmacological interaction between cannabinol and delta9-tetrahydrocannabinol. Psychopharmacology 41:277-284.
23. Weinberg AD, Dimen EM, Simon GS, Harris LS, and Borzelleca JF (1977) Measurements of weight and activity in male mice following inhalation of cannabis smoke in a controlled smoke exposure chamber. Toxicol Appl Pharmacol 42:301-307.
24. Welburn PJ, Starmer GA, Chesher GB, and Jackson DM (1976) Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacology 46:83-85.
25. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, and Martin BR (1998) Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 285:995-1004.
26. Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, and Williamson EM (2003) Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? J Pharm Pharmacol 55:1687-1694.
27. 9-THC in normal subjects. Psychopharmacology 76:245-250.
28. 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch Int Pharmacodyn Ther 269:12-19.